Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA
7 affiliations
- 1UH Seidman Cancer Center, Cleveland, Ohio, USA
- 2Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
- 3Carbone Cancer Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA
- 4Memorial Sloan Kettering Cancer Center, New York, New York, USA
- 5NewYork-Presbyterian Weill Cornell Medical Center, New York, New York, USA
- 6Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
- 7National Institutes of Health National Cancer Institute, Bethesda, Maryland, USA
Abstract
Introduction: Prostate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outcomes and limited curative treatment options. Within this group, a subset of patients exhibit oligometastatic disease, defined by a limited number of metastases, which may represent a distinct clinical entity with potential for long-term disease control. Emerging evidence suggests that metastasis-directed radiotherapy (MDRT), including stereotactic body radiation therapy (SBRT), may improve progression-free survival in this population. However, current evidence is largely limited to phase II trials in the metachronous setting and retrospective studies in the synchronous setting. Furthermore, predictive biomarkers of treatment response in these patients remain undefined. We aim to evaluate, within a large randomised multicentre phase II trial, the efficacy and biological impact of MDRT in men with de novo oligometastatic PCa.
Methods and analysis: Patients with de novo oligometastatic hormone-sensitive prostate cancer (omHSPC), defined as up to 10 sites of metastatic disease by prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT or up to five sites of metastatic disease by conventional imaging, are randomised (1:1) to standard of care (SOC) or SOC plus MDRT. SOC includes 12 months of androgen deprivation therapy plus an androgen receptor pathway inhibitor, with definitive treatment to the prostate by radiotherapy (RT). A predefined subset is allowed to undergo radical prostatectomy if clinically appropriate. MDRT involves SBRT to all metastatic sites identified on conventional imaging or PSMA PET/CT. Target enrolment is 200 patients, stratified by diagnostic imaging modality, number of bone metastases, plan to MDRT all sites of metastases and local therapy approach.
Prostate RT may be delivered using moderate (20 fractions) or ultra-hypofractionation (five fractions), with optional simultaneous-integrated-boost to dominant intraprostatic lesions. MDRT regimens aim for a biologically effective dose ≥100 Gy (α/β=1.5) using 1–5 fractions. Gross tumour volumes are delineated based on MRI, CT and PSMA PET/CT.
The primary endpoint is failure-free survival, defined using cause-specific PCa death. The study is powered at 80% to detect a HR of 0.58 using a one-sided alpha of 0.05. Secondary endpoints include radiographic progression-free survival, overall survival (OS), time to next intervention, time to castration-resistant PCa, PCa-specific mortality and patient-reported outcomes. Biospecimen collection and imaging data will support future translational analyses. Data from this trial is preplanned to be pooled with the STAMPEDE 2 ( NCT06320067 ) trial, a phase III randomised trial to assess OS benefit of MDRT in men with de novo omHSPC.
Ethics and dissemination: This clinical trial is approved by the Case Comprehensive Cancer Center Institutional Review Board (STUDY20231440). The results will be disseminated via peer-reviewed scientific journals and conference presentations.
Trial registration number: NCT06150417 ( https://clinicaltrials.gov/study/NCT06150417 )
Related
- Intramedullary Spinal Cord Metastasis From Oligometastatic Melanoma of Unknown Primary Treated With Stereotactic Body Radiotherapy.
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
- Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
- Metastasis-Directed Therapy Versus Systemic Therapy in Oligometastatic Endometrial Carcinoma Recurrence: A Population-Based Registry Analysis
- Comparative outcomes of radical prostatectomy, radiotherapy, and radiotherapy plus androgen deprivation therapy for high-risk and very high-risk prostate cancer: a narrative review
BibTeX
@article{lichtmanmikol2026metastasisdirected,
title = {{Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA}},
author = {Samuel Lichtman-Mikol and Joshua M Lang and Himanshu Nagar and Raed Zuhour and Kevin V Chaung and Nicholas G Zaorsky and Soumyajit Roy and Prateek M Mendiratta and Jonathan E Shoag and James R Janopaul-Naylor and Francesca Khani and Edward M Schaeffer and Christos E Kyriakopoulos and Pedro Barata and Jason R Brown and Jorge A Garcia and Christopher E Barbieri and Yilun Sun and Peter L Choyke and Daniel E Spratt and Angela Y Jia},
journal = {BMJ Open},
year = {2026},
month = oct,
doi = {10.1136/bmjopen-2026-116331},
url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-116331},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA
AU - Samuel Lichtman-Mikol
AU - Joshua M Lang
AU - Himanshu Nagar
AU - Raed Zuhour
AU - Kevin V Chaung
AU - Nicholas G Zaorsky
AU - Soumyajit Roy
AU - Prateek M Mendiratta
AU - Jonathan E Shoag
AU - James R Janopaul-Naylor
AU - Francesca Khani
AU - Edward M Schaeffer
AU - Christos E Kyriakopoulos
AU - Pedro Barata
AU - Jason R Brown
AU - Jorge A Garcia
AU - Christopher E Barbieri
AU - Yilun Sun
AU - Peter L Choyke
AU - Daniel E Spratt
AU - Angela Y Jia
PY - 2026
DA - 2026/10/06
JO - BMJ Open
DO - 10.1136/bmjopen-2026-116331
UR - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-116331
AB - Introduction: Prostate cancer (PCa) is the most commonly diagnosed cancer in men worldwide. A rising proportion of men present with de novo metastatic disease, a state associated with poor survival outcomes and limited curative treatment options. Within this group, a subset of patients exhibit oligometastatic disease, defined by a limited number of metastases, which may represent a distinct clinical entity with potential for long-term disease control. Emerging evidence suggests that metastasis-directed radiotherapy (MDRT), including stereotactic body radiation therapy (SBRT), may improve progression-free survival in this population. However, current evidence is largely limited to phase II trials in the metachronous setting and retrospective studies in the synchronous setting. Furthermore, predictive biomarkers of treatment response in these patients remain undefined. We aim to evaluate, within a large randomised multicentre phase II trial, the efficacy and biological impact of MDRT in men with de novo oligometastatic PCa. Methods and analysis: Patients with de novo oligometastatic hormone-sensitive prostate cancer (omHSPC), defined as up to 10 sites of metastatic disease by prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/CT or up to five sites of metastatic disease by conventional imaging, are randomised (1:1) to standard of care (SOC) or SOC plus MDRT. SOC includes 12 months of androgen deprivation therapy plus an androgen receptor pathway inhibitor, with definitive treatment to the prostate by radiotherapy (RT). A predefined subset is allowed to undergo radical prostatectomy if clinically appropriate. MDRT involves SBRT to all metastatic sites identified on conventional imaging or PSMA PET/CT. Target enrolment is 200 patients, stratified by diagnostic imaging modality, number of bone metastases, plan to MDRT all sites of metastases and local therapy approach. Prostate RT may be delivered using moderate (20 fractions) or ultra-hypofractionation (five fractions), with optional simultaneous-integrated-boost to dominant intraprostatic lesions. MDRT regimens aim for a biologically effective dose ≥100 Gy (α/β=1.5) using 1–5 fractions. Gross tumour volumes are delineated based on MRI, CT and PSMA PET/CT. The primary endpoint is failure-free survival, defined using cause-specific PCa death. The study is powered at 80% to detect a HR of 0.58 using a one-sided alpha of 0.05. Secondary endpoints include radiographic progression-free survival, overall survival (OS), time to next intervention, time to castration-resistant PCa, PCa-specific mortality and patient-reported outcomes. Biospecimen collection and imaging data will support future translational analyses. Data from this trial is preplanned to be pooled with the STAMPEDE 2 ( NCT06320067 ) trial, a phase III randomised trial to assess OS benefit of MDRT in men with de novo omHSPC. Ethics and dissemination: This clinical trial is approved by the Case Comprehensive Cancer Center Institutional Review Board (STUDY20231440). The results will be disseminated via peer-reviewed scientific journals and conference presentations. Trial registration number: NCT06150417 ( https://clinicaltrials.gov/study/NCT06150417 )
SN - 2044-6055
SN - 2044-6055
ER -